These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 1789811)
21. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Martens LL; Guibert R Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684 [TBL] [Abstract][Full Text] [Related]
22. [Multicenter study for aggressive lipid-lowering strategy by HMG-CoA reductase inhibitors]. Ogawa H; Kojima S; Sakamoto T Nihon Ronen Igakkai Zasshi; 2009 Jan; 46(1):26-8. PubMed ID: 19246828 [No Abstract] [Full Text] [Related]
23. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930 [TBL] [Abstract][Full Text] [Related]
24. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Farnier M Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929 [TBL] [Abstract][Full Text] [Related]
26. Statins and risk of coronary heart disease. Ebrahim S; Smith GD JAMA; 2000 Jun; 283(22):2935-6. PubMed ID: 10865267 [No Abstract] [Full Text] [Related]
27. Beyond statins: what to expect from add-on lipid regulating therapy? Laufs U; Weintraub WS; Packard CJ Eur Heart J; 2013 Sep; 34(34):2660-5. PubMed ID: 23832488 [No Abstract] [Full Text] [Related]
28. [Guideline for management of lipid metabolism]. Ishibashi S Nihon Rinsho; 2002 Sep; 60 Suppl 9():675-8. PubMed ID: 12387068 [No Abstract] [Full Text] [Related]
29. Gauging the impact of statins using number needed to treat. Kumana CR; Cheung BM; Lauder IJ JAMA; 1999 Nov; 282(20):1899-901. PubMed ID: 10580441 [No Abstract] [Full Text] [Related]
30. How do HMG-CoA reductase inhibitors prevent stroke? Bedi A; Flaker GC Am J Cardiovasc Drugs; 2002; 2(1):7-14. PubMed ID: 14727994 [TBL] [Abstract][Full Text] [Related]
31. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre. Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067 [TBL] [Abstract][Full Text] [Related]
36. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterol-lowering agents. Gordon DJ; Rifkind BM Ann Intern Med; 1987 Nov; 107(5):759-61. PubMed ID: 3662286 [No Abstract] [Full Text] [Related]
37. Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors. Lopez LM Am J Health Syst Pharm; 2002 Jun; 59(12):1173-9; quiz 1180-2. PubMed ID: 12073858 [TBL] [Abstract][Full Text] [Related]
38. The analysis by Manuel and colleagues creates controversy with headlines, not data. Genest J; McPherson R; Frohlich J; Fodor G CMAJ; 2005 Apr; 172(8):1033-4; discussion 1037. PubMed ID: 15824410 [No Abstract] [Full Text] [Related]